Santaris Pharma A/s

The University of North Carolina at Chapel Hill

Ercole Biotech, Inc.

Henrik Ørum

Henrik Frydenlund Hansen

Ryszard M Kole

Troels Koch

Claes Wahlestedt

Joacim Elmén

Zicai Liang

Joachim Elmén

Anders Malling Sørensen

Peter L Sazani

Maria Graziewicz

The present invention is directed to novel double-stranded short interfering (siRNA) analogues comprising locked nucleic acid (LNA) monomers. Such compounds induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). The compounds disclosed herein has improved properties compared to non-modified siRNAs and may, accordingly, be useful as therapeutic agents, e.g., in the treatment of various cancer forms. More particularly, the present invention is directed to siRNA analogues comprising a sense strand and an antisense strand, wherein each strand comprises 12-35 nucleotides and wherein the siRNA analogues comprise at least one locked nucleic acid (LNA) monomer.

Short interfering RNA (siRNA) analogues

The present invention relates to tumor necrosis factor (TNF) antagonists and corresponding nucleic acids derived from tumor necrosis factor receptors (TNFRs) and their use in the treatment of inflammatory diseases. These proteins are soluble secreted decoy receptors that bind to TNF and prevent TNF from signaling to cells. In particular, the proteins are mammalian TNFRs that lack exon 7 and which can bind TNF and can act as a TNF antagonist.

Soluble TNF receptors and their use in treatment of disease

Growing community of inventors

Vaerlose, Denmark

Henrik Ørum